Can a gene-silencing drug calm overactive complement in kidney disease?
NCT ID NCT07730632
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This phase II trial tests an experimental drug called QLS7305 in people with several kidney diseases driven by overactivation of the complement system, a part of the immune system. The drug is a small interfering RNA (siRNA) designed to reduce production of complement protein C3, potentially lowering inflammation and protein leakage into urine. Researchers are enrolling about 60 adults with IgA nephropathy, C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, or primary membranous nephropathy to see if the drug can safely reduce proteinuria over 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QLS7305, an experimental siRNA drug that targets complement C3 to reduce kidney inflammation
- What this could lead to
- If successful, this could provide a new treatment option for several complement-mediated kidney diseases, potentially slowing disease progression.
- What could go wrong
- This is an early phase II trial with only 60 participants, so results may not confirm efficacy or safety. The drug targets a key immune pathway, which could increase infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for C3 GLOMERULOPATHY (C3G) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tackle a tough kidney disease?
- Can a smarter antibody outsmart a kidney disease that resists standard treatment?
- Can engineered immune cells tame autoimmune kidney disease?
- Can a targeted therapy tame rare kidney diseases in daily practice?
- Can a pill calm the immune attack on kidneys?
- Engineered immune cells take aim at childhood autoimmune diseases